Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 4 Date: 14 Oct 2024
Reviewer:  Kazuo Kobayashi
Reviewer's report:
Thank you for your revised submission titled "Efficacy and Safety of Nivolumab in Advanced
Gastric and Gastroesophageal Junction Cancer: A Meta-Analysis of Randomized Controlled
Trials."
Upon reviewing the revised manuscript, I am pleased to inform you that all the comments
and suggestions raised during the initial review have been addressed comprehensively. The
clarification of methodology, expansion of the discussion, and reduction of redundancy have
significantly enhanced the quality of the manuscript. The supplementary data, as well as the
point-by-point responses to the reviewers' concerns, are thorough and well-articulated.
At this point, I do not have any further comments or recommendations for revision, as the
manuscript now meets the necessary standards for publication.
Thank you again for your diligence in addressing the feedback. I look forward to seeing the final
published version.
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 4 Date: 14 Oct 2024
Reviewer:  Kazuo Kobayashi
Reviewer's report:
Thank you for your revised submission titled "Efficacy and Safety of Nivolumab in Advanced
Gastric and Gastroesophageal Junction Cancer: A Meta-Analysis of Randomized Controlled
Trials."
Upon reviewing the revised manuscript, I am pleased to inform you that all the comments
and suggestions raised during the initial review have been addressed comprehensively. The
clarification of methodology, expansion of the discussion, and reduction of redundancy have
significantly enhanced the quality of the manuscript. The supplementary data, as well as the
point-by-point responses to the reviewers' concerns, are thorough and well-articulated.
At this point, I do not have any further comments or recommendations for revision, as the
manuscript now meets the necessary standards for publication.
Thank you again for your diligence in addressing the feedback. I look forward to seeing the final
published version.
Please review this paper.
user
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 4 Date: 14 Oct 2024
Reviewer:  Kazuo Kobayashi
Reviewer's report:
Thank you for your revised submission titled "Efficacy and Safety of Nivolumab in Advanced
Gastric and Gastroesophageal Junction Cancer: A Meta-Analysis of Randomized Controlled
Trials."
Upon reviewing the revised manuscript, I am pleased to inform you that all the comments
and suggestions raised during the initial review have been addressed comprehensively. The
clarification of methodology, expansion of the discussion, and reduction of redundancy have
significantly enhanced the quality of the manuscript. The supplementary data, as well as the
point-by-point responses to the reviewers' concerns, are thorough and well-articulated.
At this point, I do not have any further comments or recommendations for revision, as the
manuscript now meets the necessary standards for publication.
Thank you again for your diligence in addressing the feedback. I look forward to seeing the final
published version.
assistant